ENTITY
Cogstate Ltd

Cogstate Ltd (CGS AU)

12
Analysis
Health CareAustralia
CogState Limited manufactures and distributes diagnostic and therapeutic products associated with neurological disorders and the measurement of cognitive functions.
more
bullishCogstate Ltd
06 May 2023 07:22Broker

Cogstate - Donanemab Strikes Second ‘home Run’ for AD Drug Development

Eli Lilly has reported positive results from its Donanemab confirmatory phase 3 study, meeting both primary and secondary endpoints.

Logo
349 Views
Share
bullishCogstate Ltd
21 Apr 2023 22:43Broker

Cogstate - Eyes on the Prize Despite a Temporary Sales Slowdown

CGS provided a Q3’FY23 trading update with group revenue of $10.9m, +18% vs pcp or $30.5m YTD. New clinical trial (CT) contract sales have been...

Logo
371 Views
Share
bullishCogstate Ltd
04 Mar 2023 08:13Broker

Cogstate - Remembering What Matters

CGS’s result was largely pre-announced with rev of $19.5m and EBIT -$0.2m. Clinical trial segment rev was $17.1m, -18% vs pcp impacted by c.$3.3m...

Logo
291 Views
Share
bullishCogstate Ltd
04 Mar 2023 07:46Broker

Cogstate - Down but Not Out

Delayed clinical trials affected 1H'FY23 revenue, resulting in a -12% decrease to $17.1m, with c.$5m of revenue moved to FY24+.

Logo
282 Views
Share
bullishCogstate Ltd
12 Nov 2022 06:59Broker

Cogstate - Is History About to Repeat Itself?

A commercially successful drug would warrant new funding to expand its applications. Most of the lifetime investment into a drug occurs after first...

Logo
313 Views
Share
x